Star Roe, APRN
Family · Barboursville, WVNPI 1790393577
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,500 of the $55,212 with a category attached, or 75.2%. AbbVie accounts for 85.7% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2023 at $26,863 and has fallen 62.0% since, to $10,201 in 2025. Among family clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 658 payments — averaging $83.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$47K
- Jazz Pharmaceuticals Inc.$2K
- Harmony Biosciences LLC$952
- Alkermes, Inc.$714
- Teva Pharmaceuticals USA, Inc.$679
- Axsome Therapeutics, Inc.$653
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$41,50075%
- Travel & lodging$1,4963%
- Food & beverage$11,49421%
- Education$7221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 235 | $47,306 |
| Jazz Pharmaceuticals Inc. | 97 | $1,788 |
| Harmony Biosciences LLC | 60 | $952 |
| Alkermes, Inc. | 39 | $714 |
| Teva Pharmaceuticals USA, Inc. | 38 | $679 |
| Axsome Therapeutics, Inc. | 29 | $653 |
| Otsuka America Pharmaceutical, Inc. | 28 | $536 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 26 | $495 |
| Corium, LLC | 31 | $430 |
| Lundbeck LLC | 11 | $180 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $162 |
| GSK | 4 | $151 |
| Avadel CNS Pharmaceuticals, LLC | 7 | $149 |
| Biohaven Pharmaceuticals, Inc. | 3 | $141 |
| Novo Nordisk | 3 | $137 |
| Neurocrine Biosciences, Inc. | 6 | $129 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $118 |
| Ironshore Pharmaceuticals Inc. | 4 | $89 |
| Johnson & Johnson | 4 | $88 |
| Sunovion Pharmaceuticals Inc. | 6 | $85 |
| Vanda Pharmaceuticals Inc. | 4 | $83 |
| Lilly USA, LLC | 2 | $36 |
| Smith+Nephew | 2 | $33 |
| Amgen | 1 | $21 |
| Pfizer | 1 | $18 |
| AstraZeneca | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$43,671
- LYBALVI$467
- XYWAV$266
- Austedo XR$125
- CAPLYTA$125
- SUNOSI$125
- REXULTI$124
- NURTEC ODT$111
- RYBELSUS$109
How this compares
$55,212 in reported general payments places this provider in the 95th percentile of 1,507 family providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 22 | $239,328 |
| VraylarCariprazine Hcl | 100 | $197,378 |
| AustedoDeutetrabenazine | 12 | $95,716 |
| SpravatoEsketamine Hcl | 39 | $57,098 |
| RexultiBrexpiprazole | 21 | $36,144 |
| SunosiSolriamfetol Hcl | 16 | $13,346 |
| TrintellixVortioxetine Hydrobromide | 13 | $10,311 |
| Lurasidone Hcl | 14 | $8,672 |
| VyvanseLisdexamfetamine Dimesylate | 20 | $7,675 |
| Modafinil | 43 | $7,383 |
| Divalproex Sodium ErDivalproex Sodium | 27 | $5,586 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 131 | $3,685 |
| Vilazodone Hcl | 21 | $2,974 |
| Gabapentin | 169 | $2,401 |
| Alprazolam | 368 | $2,215 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $679 | $335,04434 claims |
| AbbVieVraylar | $47,306 | $197,378100 claims |
| Johnson & JohnsonSpravato | $88 | $57,09839 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $536 | $36,14421 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $162 | $17,98633 claims |
| Axsome Therapeutics, Inc.Sunosi | $653 | $13,34616 claims |
| Lilly USA, LLCOlanzapine | $36 | $40629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,507 family providers in West Virginia.
Other family in Barboursville
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
- Angela SettleCharleston$51K
- Amber DuncanCross Lanes$44K
- Jennifer FieldsHuntington$32K
- Gina LatheyScott Depot$31K
- Jodi BillerScott Depot$29K
- Misty BareboHuntington$25K
- Anne GharibHuntington$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.